This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bailey, H. Articles by Wilding, G. Search for Related Content PubMed PubMed Citation Articles by Bailey, H. Articles by Wilding, G.

Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion¹

University of Wisconsin Clinical Cancer Center, Madison, Wisconsin 53792 [H. B., K. D. T., R. Z. A., M. B. T., D. A., J. B., G. W.], and William S. Middleton Memorial Veterans Administration Hospital, Madison, Wisconsin 53705 [G. W.]

A phase I trial of fazarabine (ara-AC, 1-ß-D-arabinofuranosyl-5-azacytosine, NSC 281272) administered as a 24-h continuous infusion was performed in 24 adults with solid tumor malignancies. The majority of patients had received prior marrow-suppressive therapy. Level 7 (54.5 mg/m²/h for 24 h) was the maximum tolerated dose since during 6 evaluable first courses, 2 episodes of grade 4 granulocytopenia and 3 episodes of grade 3 occurred. Moderate thrombocytopenia also occurred at level 7 with 3 episodes of grade 1 and 1 episode of grade 4 thrombocytopenia during 6 first course treatments. Minimal myelosuppression, principally leukopenia, was seen prior to level 7. The nadir WBC through 47 courses had a linear relationship with plasma steady-state concentrations of ara-AC. The only other toxicity noted was moderate nausea/vomiting, which did not appear to be dose related. Plasma steady-state concentrations of ara-AC were reached in all patients within 4–6 h and ranged from 1.1 µM (11 mg/m²/h for 24 h) to 7.5 µM (54.5 mg/m²/h for 24 h). The mean total body clearance of ara-AC for 47 courses, levels 1–7, was 592 ± 147 (SD) ml/min/m² which is similar to prior pharmacokinetic data from the 24-h and 72-h infusion trials of the Pediatric and Medicine Branches, respectively. There were no objective disease responses during the trial. The recommended adult phase II dose for a 24-h infusion of ara-AC is 45–50 mg/m²/h.

¹ Supported by NIH Contract NO1-CM57735.

² H. B. is a recipient of an American Cancer Society Clinical Oncology Fellowship Award (89-189).

³ Recipient of an American Cancer Society Career Development Award. To whom requests for reprints should be addressed.

Received 9/17/90. Accepted 12/ 5/90.

This article has been cited by other articles:

				J. Goffin and E. Eisenhauer DNA methyltransferase inhibitors--state of the art Ann. Onc., November 1, 2002; 13(11): 1699 - 1716. [Abstract] [Full Text] [PDF]